Gastroesophageal Junction Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-11-18Clinical Trial Update: A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma [NA]
This clinical trial studies neoadjuvant chemoradiotherapy with hypofractionated radiotherapy for esophageal and gastroesophageal junction ad…
-
CLINICAL_TRIALS research · 2024-11-15Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) [Phase 3]
This is a Phase 3 trial (MK-3475-975/KEYNOTE-975) evaluating pembrolizumab versus placebo in combination with chemotherapy and radiotherapy …
-
CLINICAL_TRIALS trial_result · 2024-11-14Clinical Trial Update: A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) [Phase 2]
A Phase 2 trial evaluating atezolizumab plus tiragolumab with chemotherapy in first-line HER2-negative unresectable, recurrent, or metastati…
-
CLINICAL_TRIALS research · 2024-11-14Clinical Trial Update: Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma [NA]
This clinical trial update reports the completion of a study evaluating tumor treating fields in combination with chemotherapy as first-line…
-
FDA approval · 2024-11-13FDA Approved: OGIVRI — Supplemental Application (Biocon Biologics Inc.)
The FDA approved a supplemental application for OGIVRI (trastuzumab-dkst) from Biocon Biologics Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) [Phase 3]
This Phase 3 trial (PREVENT) is comparing HIPEC plus FLOT to FLOT alone in gastric cancer and gastroesophageal junction adenocarcinoma. The …
-
CLINICAL_TRIALS research · 2024-11-07Clinical Trial Update: Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) [Phase 2]
Phase II trial evaluating the addition of Avelumab to chemotherapy as perioperative treatment for patients with resectable gastric cancer or…
-
CLINICAL_TRIALS research · 2024-10-30Clinical Trial Update: SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer [Phase 2]
A Phase 2 clinical trial is evaluating SHR-A1811 in combination with Apatinib for advanced gastric cancer, gastroesophageal junction adenoca…
-
CLINICAL_TRIALS research · 2024-10-24Clinical Trial Update: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer [Phase 2]
Phase 2 trial assessing oxaliplatin with or without nivolumab in combination with trifluridine/tipiracil or 5-fluorouracil for frail patient…
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer [Phase 1]
First-in-human Phase 1 trial of TORL-2-307-MAB in participants with advanced cancer, including gastric cancer, pancreatic cancer, and gastro…
-
FDA approval · 2024-10-18FDA Approved: VYLOY — Original Application (Astellas Pharma US, Inc.)
FDA approved the original Biologics License Application for VYLOY (zolbetuximab) from Astellas Pharma US, enabling its use for a gastric/gas…
-
CLINICAL_TRIALS research · 2024-10-18Clinical Trial Update: Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1 [NA]
This clinical trial evaluates whether hepatotoxicity and neurotoxicity from oxaliplatin correlate with blood levels of HMGB1 in patients wit…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction [Phase 2]
Phase 2 study evaluating atezolizumab and trastuzumab in combination with capecitabine and oxaliplatin for HER2-positive locally advanced re…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.
A clinical trial is investigating multi-omics predictors of response to immunotherapy plus chemotherapy in advanced gastric cancer and gastr…
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines [Phase 1]
Phase 1 trial updating the addition of BAY 1895344 to FOLFIRI in patients with advanced or metastatic colorectal, gastric, and gastroesophag…
-
CLINICAL_TRIALS trial_result · 2024-10-02Clinical Trial Update: Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors [Phase 1, Phase 2]
Phase 1/2 trial of BNT141 in CLDN18.2-positive gastric, pancreatic, ovarian, and biliary tract cancers. The study was terminated and results…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer [Phase 2]
This Phase 2 trial reports results for heated Mitomycin C and Cisplatin administered during surgery for gastric and gastroesophageal junctio…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of fruquintinib and sintilimab as second-line therapy for gastric cancer and gastroes…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma [Phase 1, Phase 2]
A clinical trial update describes a Phase 1/2 study of AK129, an anti-PD-1 and LAG-3 bispecific antibody, combined with chemotherapy with or…
-
CLINICAL_TRIALS research · 2024-09-05Clinical Trial Update: A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma [Phase 1, Phase 2]
This clinical trial update describes a Phase I/II study evaluating Simmitinib or irinotecan liposomes in combination with DP303c for HER2-ex…
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial evaluating disitamab vedotin in combination with trastuzumab in patients with HER2-positive gastric cancer …
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. [NA]
A multicenter Phase II basket trial at Zhejiang Cancer Hospital is evaluating hypofractionated radiotherapy or SBRT followed by immunotherap…
-
CLINICAL_TRIALS research · 2024-08-19Clinical Trial Update: Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression [Phase 2]
Phase 2 trial evaluating disitamab vedotin combined with tislelizumab and capecitabine as perioperative treatment for locally advanced, HER2…
-
CLINICAL_TRIALS trial_result · 2024-08-14Clinical Trial Update: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma [Phase 2]
A Phase 2 trial evaluating infigratinib in patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocar…
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma [Phase 1, Phase 2]
Update on AK104, a PD-1/CTLA-4 bispecific antibody, evaluated in Phase 1/2 for advanced solid tumors and as first-line therapy with mXELOX/X…